ID: ALA5209497

Max Phase: Preclinical

Molecular Formula: C27H35FN4O

Molecular Weight: 450.60

Associated Items:

Representations

Canonical SMILES:  CC1CCC(N2CCc3c(-c4ccc(CN5CCC[C@H]5C)c(F)c4)cnc(N)c3C2=O)CC1

Standard InChI:  InChI=1S/C27H35FN4O/c1-17-5-9-21(10-6-17)32-13-11-22-23(15-30-26(29)25(22)27(32)33)19-7-8-20(24(28)14-19)16-31-12-3-4-18(31)2/h7-8,14-15,17-18,21H,3-6,9-13,16H2,1-2H3,(H2,29,30)/t17?,18-,21?/m1/s1

Standard InChI Key:  NCSOXYHHFXDNEU-IDYZSHNDSA-N

Associated Targets(Human)

Serine/threonine-protein kinase receptor R3 538 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Activin receptor type-1 1516 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Bone morphogenetic protein receptor type-1A 678 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 450.60Molecular Weight (Monoisotopic): 450.2795AlogP: 5.03#Rotatable Bonds: 4
Polar Surface Area: 62.46Molecular Species: BASEHBA: 4HBD: 1
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 8.72CX LogP: 5.15CX LogD: 3.81
Aromatic Rings: 2Heavy Atoms: 33QED Weighted: 0.71Np Likeness Score: -0.66

References

1. Witten MR, Wu L, Lai CT, Kapilashrami K, Pusey M, Gallagher K, Chen Y, Yao W..  (2022)  Inhibition of ALK2 with bicyclic pyridyllactams.,  55  [PMID:34780900] [10.1016/j.bmcl.2021.128452]

Source